Open-label, Single-center Phase II Study of MLN9708 (Ixazomib) in Patients With Relapsed/Refractory Cutaneous and Peripheral T-cell Lymphomas
Phase of Trial: Phase II
Latest Information Update: 15 Nov 2017
At a glance
- Drugs Ixazomib (Primary)
- Indications T cell lymphoma
- Focus Therapeutic Use
- 10 Oct 2017 Status changed from active, no longer recruiting to completed.
- 10 Jun 2017 Biomarkers information updated
- 15 Dec 2016 Status changed from recruiting to active, no longer recruiting.